 Home > Active Ingredient News > Antitumor Therapy > J Clin Oncol: Efficacy of EGFR inhibitors in the treatment of EGFR-amplified gastroesophageal junction cancer

J Clin Oncol: Efficacy of EGFR inhibitors in the treatment of EGFR-amplified gastroesophageal junction cancer

 Last Update: 2022-05-18
 Source: Internet
 Author: User

Tags

crispr cancer

largest global companies

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

A sub-analysis of a phase 3 trial of an epidermal growth factor receptor inhibitor (EGFRi) shows that EGFRi improves outcomes in patients with EGFR-amplified gastroesophageal junction cancer (GEA), but data from a larger analysis are lacking

EGFRi improves outcomes in patients with EGFR-amplified gastroesophageal junction carcinoma (GEA), but data from larger-scale analyses are lacking

Screening of histologically definite , EGFR-amplifying variant, metastatic or unresectable GEA patients receiving EGFRi therapy from 15 tertiary cancer centers in 6 countries

Screening diagnosis

With a median follow-up of 7.

The median overall survival of patients treated with EGFRi as first-, second-, or third-line therapy was 20.

Gastroesophageal junction cancer patients with EGFR amplification variants can benefit from EGFR inhibitor therapy Gastroesophageal junction cancer patients with EGFR amplification variants can benefit from EGFR inhibitor therapy

Original source:

Steven B.

Steven B.
Maron, et al.
Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor–Amplified Gastroesophageal Cancer: Retrospective Global Experience.
Journal of Clinical Oncology.
March 29, 2022.
https://ascopubs.
org/doi/full/10.
1200 /JCO.
21.
02453.

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Bulk Peptides Kisspeptin 10 (human) /Kisspeptin 10/ Kisspeptin-10 Acetate CAS 374675-21-5

CAS No.: 374675-21-5

Pharmacy Grade

$10-13/UNIT FOB

Cediranib

CAS No.: 288383-20-0

$22/KG EXW

Upadacitinib hemihydrate API

CAS No.: 2050057-56-0

Pharmacy Grade

$35-45/G FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

80 20 company(94)

united states logo(227)

ups united states(221)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.